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THE EFFECTS OF TNF-ALPHA BLOCKERS (INFLIXIMAB AND ETANERCEPT) 
ON INFLAMATION PROCESS IN EXPERIMENTAL COLITIS MODEL 
 
ABSTRACT 
Purpose: The purpose of this study is to evaluate the effects of anti-TNF agents 
(infliximab and etanercept) on inflammation in colitis model produced by TNBS-E in 
rats. 
Material and Methods: This experimental study was carried out in Experimental 
Animals Research Laboratory of Medical Faculty by the permission of Adnan 
Menderes University Animal Experiments Ethics Committee. In this study, 50 female 
Wistar-albino rats weighing between 190-280 gr were used. Rats were divided into 
five groups as follows; Group I: control group, Group II: TNBS-E colitis group, Group 
III: TNBS-E colitis treated with 5 mg/kg infliximab, Group IV: TNBS-E colitis treated 
with 5mg/kg etanercept, Group V: TNBS-E colitis treated with both 5 mg/kg infliximab 
and 5 mg/kg etanercept. A mixture of 37% ethanol and 25 mg TNBS was given by 
rectal route to create colitis. Drugs in the treatment group were administered 
subcutaneously in the second and sixth days. The subjects were sacrificed on the 
seventh day. Blood and colonic tissue samples were taken for biochemical analysis 
(TNF-alpha, interleukin-6, glutathion, glutathion peroxidase, catalase, superoxide 
dismutase in plasma and TNF-alpha, malondialdehyde, myeloperoxidase, superoxide 
dismutase, glutathion, glutathion reductase, glutathion peroxidase, catalase in tissue) 
and histopathologic evaluation. 
Results: In our study, tissue TNF-alpha and myeloperoxidase levels significantly 
decreased in all three treatment groups (infliximab, etanercept, 
infliximab+etanercept) (p<0,05). Plasma TNF-alpha levels significantly decreased in 
etanercept and infliximab+etanercept treatment groups (p<0,05). Etanercept 
treatment significantly reduced plasma interleukin-6 levels (p<0,05). While plasma 
glutathion levels in all three treatment groups decreased significantly, plasma 
catalase levels also decreased by etanercept and infliximab+etanercept treatments 
(p<0,05). Histopathological scores of etanercept and infliximab+etanercept treatment 
groups showed significant improvement (p<0,05). 
Conclusion: It has been shown that anti-TNF agents have significant effects on 
experimental colitis and etanercept may be a good alternative in anti-TNF treatment. 
Further studies may help to demonstrate the effects of etanercept in clinical practice. 
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